David Vereide
Impact in
- Oncology top 10%
- Viral-associated cancers and disorders
Papers in
-
- Pluripotent Stem Cells Research 5
- Congenital heart defects research 2
- Angiogenesis and VEGF in Cancer 1
- Oncology 5
- Viral-associated cancers and disorders 5
- Co-authors
- Bill Sugden (5 shared papers)James A. Thomson (7 shared papers)Li‐Fang Chu (3 shared papers)Brian E. McIntosh (3 shared papers)Ron Stewart (3 shared papers)Zhonggang Hou (1 shared paper)Christina Kendziorski (1 shared paper)Daniel Mamott (1 shared paper)
- Journals
- Stem Cell Reports (3 papers)Journal of Virology (1 paper)Seminars in Cancer Biology (1 paper)Advances in cancer research (1 paper)Genome biology (1 paper)
- Partner nations
- United StatesGermany
In The Last Decade
David Vereide
12 papers receiving 950 citations
Peers
Comparison fields: 5 of 65
- Oncology 305
- Cancer Research 126
- Molecular Biology 580
- Biophysics 44
- Pathology and Forensic Medicine 121
Countries citing papers authored by David Vereide
This map shows the geographic impact of David Vereide's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Vereide with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Vereide more than expected).
Fields of papers citing papers by David Vereide
This network shows the impact of papers produced by David Vereide. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Vereide. The network helps show where David Vereide may publish in the future.
Co-authors
The 25 scholars most cited alongside David Vereide, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 313 | |
| 2 | 2015 | 164 | |
| 3 | 2013 | 143 | |
| 4 | 2011 | 118 | |
| 5 | 2010 | 71 | |
| 6 | 2009 | 54 | |
| 7 | 2009 | 31 | |
| 8 | 2010 | 25 | |
| 9 | 2014 | 21 | |
| 10 | 2018 | 8 | |
| 11 | 2018 | 7 | |
| 12 | 2025 | 1 |
About David Vereide
David Vereide is a scholar working on Molecular Biology, Oncology, Pathology and Forensic Medicine, Rheumatology and Surgery, having authored 12 papers that have together received 956 indexed citations. Recurring topics across this work include Pluripotent Stem Cells Research (5 papers), Viral-associated cancers and disorders (5 papers), Lymphoma Diagnosis and Treatment (4 papers), Eosinophilic Disorders and Syndromes (3 papers), Congenital heart defects research (2 papers), Angiogenesis and VEGF in Cancer (1 paper), Electrospun Nanofibers in Biomedical Applications (1 paper) and Xenotransplantation and immune response (1 paper). The work is most often cited by research in Oncology (305 citations), Cancer Research (126 citations), Molecular Biology (580 citations), Biophysics (44 citations) and Pathology and Forensic Medicine (121 citations). David Vereide has collaborated with scholars based in United States and Germany. Frequent co-authors include Bill Sugden, James A. Thomson, Li‐Fang Chu, Brian E. McIntosh, Ron Stewart, Zhonggang Hou, Christina Kendziorski, Daniel Mamott, Jue Zhang and Jeea Choi. Their work appears in journals such as Stem Cell Reports, Journal of Virology, Seminars in Cancer Biology, Advances in cancer research and Genome biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.